Last reviewed · How we verify

Medical Management

CVRx, Inc. · Phase 2 active Small molecule ✓ Verified Jun 2026

Medical Management is a Small molecule drug developed by CVRx, Inc.. It is currently in Phase 2 development. Also known as: Antiplatelet therapy e.g. aspirin, clopidogrel, ticagrelor, dipyridamole, cilostazol, or a combination of these medications, Anticoagulation e.g warfarin, direct oral anticoagulants, misoprostol, mifepristone.

Medical Management refers to the application of various interventions, including educational programs, oral iron therapy, and point-of-care STI testing, to manage conditions such as breast cancer, iron deficiency anemia, nutrition disorders, growth retardation, and sexually transmitted infections. The effectiveness of these interventions can be evaluated through clinical trials, such as the study "Impact of OncoDoc2 on Guideline Compliance in the Management of Breast Cancer," which assessed the impact of a decision support system on multidisciplinary staff meeting decisions.

Likelihood of approval
15.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameMedical Management
Also known asAntiplatelet therapy e.g. aspirin, clopidogrel, ticagrelor, dipyridamole, cilostazol, or a combination of these medications, Anticoagulation e.g warfarin, direct oral anticoagulants, misoprostol, mifepristone, AAD treatment
SponsorCVRx, Inc.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Medical Management

What is Medical Management?

Medical Management is a Small molecule drug developed by CVRx, Inc..

Who makes Medical Management?

Medical Management is developed by CVRx, Inc. (see full CVRx, Inc. pipeline at /company/cvrx-inc).

Is Medical Management also known as anything else?

Medical Management is also known as Antiplatelet therapy e.g. aspirin, clopidogrel, ticagrelor, dipyridamole, cilostazol, or a combination of these medications, Anticoagulation e.g warfarin, direct oral anticoagulants, misoprostol, mifepristone, AAD treatment.

What development phase is Medical Management in?

Medical Management is in Phase 2.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing